

# New Developments in Clinical Pharmacy and Clinical Pharmacology

June 29, 2019

Reims, France



- 8:00-9:00**      **Registration/Coffee**  
**Hotel La Paix, Reims**  
**9 Rue Buirette**
- 9:00**      *Welcome*  
**Hartmut Derendorf**  
University of Florida
- 9:15**      *UF College of Pharmacy—Rising to Greater Heights*  
**Julie Johnson**  
University of Florida
- 9:30**      *UF's International Engagement*  
**Leonardo Villalón**  
University of Florida
- 9:45**      *HCV: The Final Cure*  
**David Nelson**  
University of Florida
- 10:00**      *Kratom Research at UF*  
**Chris McCurdy & Lance McMahon**  
University of Florida
- 10:30**      Coffee Break
- 11:00**      *Outcomes with Pharmacogenetic Implementation in Clinical Practice*  
**Larisa Cavallari**  
University of Florida

- 11:15**      *UF Health Precision Medicine Program – Real World Preemptive Genotyping: The Future Is Bright*  
**Rhonda Cooper-DeHoff**  
University of Florida
- 11:30**      *Pharmacogenomics to Improve AML Treatment*  
**Jatinder Lamba**  
University of Florida
- 11:45**      *Opioid Overdose & Addiction Epidemic: Pharmacological Treatment Advances from the '70s to Present*  
**Mark Gold**  
University of Florida
- 12:00**      *Printed Medicines – Paving the Way to Precision Medicines*  
**Jörg Breitkreutz**  
University of Düsseldorf
- 12:15**      **Presentation of the 2019 Global Gator Award**
- Previous Awardees:**
- |      |                 |
|------|-----------------|
| 2017 | Larry Lesko     |
| 2015 | Paul Doering    |
| 2013 | William Riffey  |
| 2011 | Emil Pop        |
| 2009 | Willy Roth      |
| 2007 | Marcus Brewster |
| 2005 | Hans Schreier   |
- 12:30**      **Lunch**

- 14:00** *The Tantalizing Potential of Real World Data in Drug Development*  
**Larry Lesko**  
University of Florida
- 14:15** *Deep Learning on Real-World Data: Overview and Application in Early Drug Development*  
**Janick Weerpals**  
Roche, Munich
- 14:30** *Size Does Matter*  
**Stephan Schmidt**  
University of Florida
- 14:45** *PharMetrix – More than a Decade...*  
**Charlotte Kloft**  
Free University of Berlin
- 15:00** *Development of Inhaled Antibiotics for the Treatment of Tuberculosis*  
**Bernd Meibohm**  
University of Tennessee
- 15:15** *Bioequivalence Assessment of Inhalation Drugs- Suggestions for a More Streamlined Development Approach*  
**Günther Hochhaus & Jürgen Bulitta**  
University of Florida
- 15:30** **Coffee Break**
- 16:00** *Marrying Laboratory and Data Science to Evaluate Otic Quinolone Safety*  
**Almut Winterstein**  
University of Florida

- 16:15** *Pharmacist-Physician Partnership in the U.S.*  
**Patrick Antonelli**  
University of Florida
- 16:30** *Establishing New Pharmaceutical Care Services in German Pharmacies*  
**Ina Richling**  
Iserlohn, Germany; University of Florida
- 16:45** *Integrating Pharmacometrics and Pharmacoconomics to Predict the Clinical and Cost Effectiveness of Future Generic Anticoagulants*  
**Joshua Brown**  
University of Florida
- 17:00** A Scientist's And Product's Lifecycle: Successes, Failures And Overcoming The Odds - Or What A Long, Strange Trip It's Been  
Robert Bell  
Drug Biotechnology Development, Tampa
- Bus Transfer to Epernay Reception and Group Photo**
- 18:30** **Gator Fest and Dinner**  
Mercier, Epernay

## Previous Symposia

2017	11 <sup>th</sup> Symposium	Düsseldorf, Germany
2015	10 <sup>th</sup> Symposium	Utrecht, The Netherlands
2013	9 <sup>th</sup> Symposium	Garmisch-Partenkirchen, Germany
2011	8 <sup>th</sup> Symposium	Graz, Austria
2009	7 <sup>th</sup> Symposium	Stresa, Italy
2007	6 <sup>th</sup> Symposium	Munich, Germany
2005	5 <sup>th</sup> Symposium	Leuven, Belgium
2003	4 <sup>th</sup> Symposium	Vienna, Austria
2001	3 <sup>rd</sup> Symposium	Dresden, Germany
1999	2 <sup>nd</sup> Symposium	Reims, France
1997	1 <sup>st</sup> Symposium	Münster, Germany




**Hartmut Derendorf, Ph.D.,** is Distinguished Professor Emeritus in the Department of Pharmaceutics at the University of Florida College of Pharmacy in Gainesville. Prof. Derendorf has published over 490 scientific publications and ten textbooks in English and German. He is Editor or Associate Editor of five Journals such as the Journal of Clinical Pharmacology. Prof. Derendorf has served as President of the American College of Clinical

Pharmacology (ACCP) and President of the International Society of Antiinfective Pharmacology (ISAP). He was awarded the Distinguished Research Award, the Mentorship Award and the Nathaniel T. Kwit Distinguished Service Award of ACCP, the Research Achievement Award in Clinical Science of the American Association of Pharmaceutical Sciences (AAPS), the Leadership Award of the International Society of Pharmacometrics (ISOP), the Volwiler Award of the American Association of Colleges of Pharmacy (AAPC) and the ASCPT Mentor Award. He also served as the 18<sup>th</sup> University of Florida Distinguished Alumni Professor.




**Julie A. Johnson, Pharm.D.,** is Dean of the University of Florida College of Pharmacy and Distinguished Professor of Pharmacy and Medicine. Dr. Johnson's research focuses on cardiovascular pharmacogenomics and genomic medicine implementation, for which she has been named a Clarivate Analytics Highly Cited Scientist in 2015, 2016, 2017 and 2018, indicating she is in the top 1% of the most highly cited scientists in her field globally. She has led clinical

pharmacogenetics implementation at UF Health since 2011 and has been funded by NHGRI's IGNITE network (focused on genomic medicine implementation) since 2013. Dr. Johnson has served in numerous capacities with the NIH, the Food and Drug Administration, and leadership roles in multiple professional societies, including as President of the American Society of Clinical Pharmacology and Therapeutics. She has received numerous awards and honors and was elected to the National Academy of Medicine in 2014.



**Leonardo Villalón, Ph.D.** is Dean of the International Center and Professor of Political Science and African Studies at the University of Florida, where he also coordinates the UF Sahel Research Group. He is a specialist on the politics of the Francophone countries of the African Sahel (Senegal, Mali, Niger, Burkina Faso, Mauritania, and Chad), in particular the political role of Islam on democratization, education, and political stability. His research has been supported by Fulbright and Carnegie

Scholars awards, and by grants from the US State Department, the UK Department for International Development (DfID), the US DOD Minerva Initiative, and the Sahel and West Africa Club of the OECD. He has published numerous works on the Sahel, and is editor of the forthcoming *Oxford Handbook of the African Sahel*. He is past president of the West African Research Association, and currently serves as Chair of the board of directors of the Council of American Overseas Research Centers (CAORC).



**David R. Nelson, M.D.**, serves as senior vice president for health affairs and president, UF Health. In this role, he is responsible for six health science colleges, five research centers, and UF Health, which operates hospitals and faculty practices in Gainesville and Jacksonville. A professor of medicine and expert in liver disease, Dr. Nelson's record of academic achievement includes more than \$100 million in research funding and more than 200 publications. He plays a leadership role in developing national and international guidelines related to the management of viral hepatitis, has co-

authored the US treatment guidelines for hepatitis C, the CPIC guidelines for the use of genomic-guided HCV therapy, and represents the United States on the World Health Organization HCV guidelines committee. He leads an international hepatitis C research network, which has developed an innovative partnership with industry, academia, and the FDA leveraging real-world evidence to enhance the safety and effectiveness of new therapies approved for hepatitis C treatment. In recognition of this outstanding public-private partnership he received the Regulatory Science Excellence Honor Award from the FDA in 2018.



**Lance McMahon, Ph.D.**, is Professor and Chair of the Department of Pharmacodynamics at the University of Florida College of Pharmacy. He previously held the position of Tenured Associate Professor of Pharmacology at the University of Texas Health Science Center in San Antonio. He obtained a PhD in Behavioral Neuroscience from Texas A&M University, and was a postdoctoral fellow in the Department of Pharmacology and Toxicology at the University of

Texas Medical Branch in Galveston. He has been continuously funded by the National Institute on Drug Abuse since 2002 as PI of 6 R01 grants, an R21, and a U grant. He is a regular member of the Center for Scientific Review NIH study section Biobehavioral Regulation, Learning and Ethology. He served on the Executive Board of the Behavioral Pharmacology Division of the American Society of Pharmacology and Experimental Therapeutics. Dr. McMahon's laboratory integrates principles of behavior and receptor theory to identify CNS mechanisms responsible for drug dependence, and novel pharmacological strategies that maximize therapeutics and minimize abuse liability.



**Christopher McCurdy, Ph.D.**, is a broadly trained medicinal chemist, behavioral pharmacologist and pharmacist whose research focuses on the design, synthesis and development of drugs to treat pain and drug abuse. For over 20 years, much of his research has focused on opioid, Neuropeptide FF and sigma receptor ligand/probe design, synthesis, pharmacological evaluation and development.

He has been successful in discovering unique and selective tools for sigma receptors, NPFF receptors and opioid receptors. He is an internationally recognized expert on Kratom (*Mitragyna speciosa*), that is under investigation for opioid withdrawal syndrome. A significant portion of his career has been dedicated to the development of novel sigma receptor ligands, in collaboration with a variety of interdisciplinary groups, to generate and optimize selective ligands which could serve as critical experimental tools, and more recently, as potential medication development leads to attenuate the effects of cocaine, methamphetamine and pain. Most notably, he has developed a PET/MR imaging diagnostic agent for visualizing the origins of chronic, neuropathic pain by interacting with sigma receptors at the site of nerve damage. First-in-human studies are currently underway in a Phase 0 trial. In addition to his discovery chemistry roles, McCurdy serves as the director of the UF Translational Drug Development Core.



**Larisa H. Cavallari, Pharm.D.,** is an Associate Professor, Head of the Division of Translational Research, and Director of the Center for Pharmacogenomics and Precision Medicine at the University of Florida College of Pharmacy. She received her B.S.Pharm and Pharm.D. degrees from the University of Georgia, followed by a pharmacy practice residency at the Veterans Affairs Medical Center in Memphis, Tennessee and a fellowship in cardiovascular pharmacogenomics at the University of Florida. Her research involves discovery of genetic associations with drug response and their translation into clinical practice.



**Rhonda M. Cooper-DeHoff, Pharm.D., M.S., FCCP, FACC, FAHA,** is an associate professor, Department of Pharmacotherapy and Translational Research; and Director, Precision Medicine Program – Gainesville Campus. She is also Director for the Graduate Program in Precision Medicine and the Associate Director, Center for Pharmacogenomics and Precision Medicine. Dr. Cooper-DeHoff's area of research interest include hypertension pharmacogenetics and the factors that influence outcomes with antihypertensive treatment. She also has interest in the area of antihypertensive drug use and adverse

metabolic effects including diabetes. In total, she has nearly 200 publications and many have been of high impact, helping to define demographic, clinical, metabolic, metabolomic and genetic and pharmacogenetic factors associated with responses to antihypertensive drugs and cardiovascular outcomes with antihypertensive therapy. She is currently conducting research in the area of preemptive pharmacogenetics testing in multiple therapeutic areas.



**Jatinder Lamba, Ph.D.**, is currently Associate Professor in College of Pharmacy and UF Term at University of Florida. She has more than 20 years of expertise in the field of pharmacogenomics. Current research in her lab is focused on multi-omics approaches in pediatric AML for identification, characterization and clinical validation of markers predictive of clinical response in AML. This work has been funded by National Cancer Institute since 2008 and spans from preclinical basic research utilizing cell line model systems to translational/clinical phase in patient populations from multi-institute clinical trials. Dr. Lamba is very committed towards

training of future generation of scientist. She has trained several trainees ranging from Ph.D. students, post-doctoral fellows, Pharm D students, hematology-oncology fellows and under-graduate students. Dr. Lamba has served as chair of Pharmacogenomics –SIG at AACP and Pharmacogenomics focus group with AAPS and has served as grant reviewer for numerous NIH study sections.



**Mark S. Gold, M.D.** is a teacher of the year, translational researcher, author, mentor and inventor best known for his work on the brain systems underlying the effects of opiate drugs, cocaine and food. Gold was a Professor, Eminent Scholar, Distinguished Professor, Distinguished Alumni Professor, Chairman, Emeritus Eminent Scholar during his 25 years at the University of Florida. He was the U.F. undergraduate Pre Med Advisor, Under-represented minority mentor, and teacher of the year at the College of Medicine. His mentees include Institute Directors, Chairs, Professor, and Pharma CEOs. He was a Founding Director of the McKnight Brain Institute, pioneering neuroscience – addiction researcher funded by the NIH-NIDA-Pharma,

whose work helped to de-stigmatize addictions, mainstream addiction education and treatment. He has received numerous awards for his research and translating them into new treatments. Gold's work has been a critical part of the foundational science which established that drugs of abuse change the brain, are addicting on the basis of these changes, and can be successfully treated. He has also suggested that some changes are more easily reversed than others and that dual disorders result from drug use rather than cause them. He is an author and inventor who has published over 1000 peer reviewed scientific articles, 20 text books, popular-general audience books, and physician practice guidelines. He has received numerous awards for his research and translating them into new treatments. Gold's work has been a critical part of the foundational science which established that drugs of abuse change the brain, are addicting on the basis of these changes, and can be successfully treated. He has also suggested that some changes are more easily reversed than others and that dual disorders result from drug use rather than cause them.



**Jörg Breitkreutz, Ph.D.**, studied Pharmacy from 1987 to 1991 at the Westphalian Wilhelms-University of Münster, Germany. He finished his PhD in 1996 under supervision of Prof. Dr. Rüdiger Gröning. From 1996 to 1997 he joined Thiemann Arzneimittel GmbH in Waltrop, Germany, as the head of Product Coordination. In 1997 he went back to his home university working on his habilitation thesis “Pediatric Drug Formulations” (2004) on. In 2004 he became professor for Pharmaceutical Technology and Biopharmaceutics at the Institute of Pharmaceutics and Biopharmaceutics of Heinrich-Heine-University in Düsseldorf, Germany. and is the director of this institute today. He is heading the Paediatric Formulation group at the European Directorate for the Quality of Medicines and Healthcare (EDQM). Since 2010 he is president of the non-for-profit International Association of Pharmaceutical Technology (APV). His research focuses on pediatric and geriatric drug formulations, drug printing technologies, orphan drugs, process analytical technologies, green and sustainable medicinal products.



Lawrence J. Lesko, Ph.D., is Emeritus Professor and Founding Director of the Center for Pharmacometrics and Systems Pharmacology at the University of Florida (UF) College of Pharmacy at Lake Nona (Orlando). He started the Center in 2011 and served as its full-time Director for 5 years. He now serves as a consultant to pharmaceutical companies and as a strategic

advisory board member of several biosimulation, genomic and healthcare organizations. Dr. Lesko was the Director of the Office of Clinical Pharmacology (OCP) in the Center for Drug Evaluation and Research at the Food and Drug Administration from 1995 to 2011. He coauthored numerous Guidance for Industry including “Exposure-Response Relationships”, “Clinical Pharmacogenomics” and “Pharmacogenomics Data Submissions”. Dr. Lesko has published more than 225 peer-reviewed manuscripts. Dr. Lesko was inducted as a Fellow in the College of Physicians of Philadelphia in 2019. In 2018, Dr. Lesko received the first FDA OCP Distinguished Alumni Lectureship Award for his contributions to clinical pharmacology. Dr. Lesko also received the prestigious UF Global Gator Award in 2017 for his contributions to international drug development.



**Janick Weberpals, Ph.D.**, is a postdoctoral researcher in Data Science at the Roche Innovation Center in Munich, Germany. He holds a pharmacy degree from Philipps-University Marburg, a specialization in drug information and a Ph.D. in Epidemiology from the University of Heidelberg, Germany. He started his career as a visiting scholar at the Department of Pharmaceutical Outcomes and Policy at the University of Florida in 2014/15. During his Ph.D. studies at the German Cancer Research Center in Heidelberg he strongly focused on applied and methodological questions in the field of cancer pharmacoepidemiology. In his current role as a postdoctoral fellow at Roche he works on methods to

analyze high-dimensional real-world databases using deep learning for the application to problems in early drug development and comparative effectiveness & safety studies. He (co-) authored 20+ published manuscripts and received several awards including the Stephan-Weiland prize and the Advancement Award for best PhD Thesis in Epidemiology by the German Association for Medical Informatics, Biometry and



**Stephan Schmidt, PhD**, is an Endowed Associate Professor in the Department of Pharmaceutics at the University of Florida, College of Pharmacy in Lake Nona (Orlando), where he also serves as the Associate Director for the Center for Pharmacometrics and Systems Pharmacology. He received his B.S. (2003) in Pharmacy from the Friedrich-Alexander University in Erlangen, Germany, and his PhD (2008) in Pharmacy from the University of Florida in Gainesville, USA. Following a post-doctoral fellowship (2009-2011) at the Leiden-Amsterdam Center for Drug Research, he rejoined the University of Florida as faculty in 2012. Dr. Schmidt has been teaching Pharmacokinetics, Pharmacodynamics, and Physiologically-Based Pharmacokinetics. He

received numerous awards including the Paul Ehrlich Society for Chemotherapy Thesis Award in 2010, the University of Florida Clinical Translational Science Institute Junior Faculty Pilot Program Award in 2012, the University of Florida Excellence Award for Assistant Professors in 2013, and the Tanabe Young Investigator Award from the American College of Clinical Pharmacology (ACCP) in 2016. He was named International Educator of the Year of the College of Pharmacy in 2014, the Endowed Certara Professor at the University of Florida in 2017, and the Doctoral Thesis Mentor of the College of Pharmacy in 2019. Dr. Schmidt mentored more than 30 PhD students and post-doctoral fellows as well as more than 20 Masters students, international scholars, and visiting scientists. He has published 70 scientific manuscripts, 6 book chapters and gave more 50 presentations at national and international meetings. He is also the lead editor of a book entitled, "Applied Pharmacometrics", published in 2014 as part of an AAPS series on advancing Pharmaceutical Sciences. Dr. Schmidt serves as the Chair of the Special Interest Group on PK/PD and Systems Pharmacology of the International Pharmaceutical Federation (FIP) and the Immediate Past Chair of the Systems Pharmacology Community for the American Society for Clinical Pharmacology and Therapeutics (ASCPT). He is a Section Editor for the European Journal of Pharmaceutical Sciences and Editorial Board Member for the Journal of Clinical Pharmacology and ASCPT's Pharmacometrics and Systems Pharmacology journal.



**Charlotte Kloft, Ph.D.**, is ‘Universitaetsprofessorin’(Full Professor) and Head of Dept. Clinical Pharmacy & Biochemistry at Freie Universitaet Berlin ([www.clinical-pharmacy.eu](http://www.clinical-pharmacy.eu)). Currently, she is also Director of the Institute of Pharmacy at Freie Universitaet, President of the German Pharmaceutical Society (DPhG), section Berlin-Brandenburg, and member of the Drug Commission of German Pharmacists (AMK). After her undergraduate pharmacy studies in Mainz, she received her ‘Dr. rer. nat.,summa cum laude’ (PhD with highest honours) at Freie Universitaet. After a two-year industrial career at Sanofi in Frankfurt she continued her career in academia

with several sabbaticals at Uppsala Universitet/Sweden and received the habilitation in Clinical Pharmacy from Freie Universitaet. From 2005-2011, she was Full Professor of Clinical Pharmacy at Martin-Luther-Universitaet Halle-Wittenberg. In 2008, as Chair together with Prof. Huisenga, she founded the Graduate-Research-Training-Program PharMetRX “Pharmacometrics and Computational Disease Modelling” supported by an Industry consortium ([www.PharMetRX.de](http://www.PharMetRX.de)). Her research mission is ‘to foster rational use of medicines’ with a focus in: precision dosing, pharmacometrics/M&S of drug-disease-system/patient interactions; antineoplastics, monoclonals; vulnerable populations such as critically ill or paediatrics. As Principal Investigator her research is funded amongst others by the European Union and the Federal Ministry of Education and Researchach. She published >130 peer-reviewed articles, is co-editor of the German textbook “Klinische Pharmazie”, member of editorial boards/referee of inter-national, peer-reviewed journals and serves in several inter-/national scientific committees in the field, e.g. PK/PD Expert Meeting and Population Approach Group Europe (PAGE).



**Bernd Meibohm, Ph.D, FCP, FAAPS** is a Professor of Pharmaceutical Sciences and Associate Dean for Research and Graduate Programs at the College of Pharmacy, The University of Tennessee Health Science Center, Memphis, Tennessee. He received his B.S. in pharmacy and Ph.D. in pharmaceutics from Technical University Carolo-Wilhelmina, Braunschweig, Germany. After completion of a clinical pharmacology research fellowship at the University of Florida in 1997, he joined the faculty of the University of South Carolina, and in

1999 the University of Tennessee. Dr. Meibohm’s scientific interests include pulmonary infectious and inflammatory diseases, pediatric pharmacotherapy and the application of quantitative modeling and simulation techniques in preclinical and clinical drug development, with specific focus on therapeutic proteins. His research work has attracted more than \$40 million in extramural funding as principal and co-investigator and has resulted in over 170 scientific papers and book chapters (h-index 45), three textbooks, 170 abstracts, and over 200 invited scientific presentations to national and international audiences. Meibohm is a Fellow of the American Association of Pharmaceutical Scientists (AAPS) and the American College of Clinical Pharmacology (ACCP). He was the President for the American College of Clinical Pharmacology (ACCP) 2014-2016, the 2010 Chair for the ‘Pharmacokinetics, Pharmacodynamics and Drug Metabolism’ (PPDM) section of AAPS, and currently serves as Member-at-Large on the Board of Directors of AAPS.



**Günther Hochhaus, Ph.D.**, received his Ph.D. in 1984 at the Institute of Pharmaceutical Chemistry, Westf. Wilhelms University (Münster, Germany). He completed a post-doctoral fellowship at the University of California-San Francisco and subsequently joined the University of Florida's College of Pharmacy as an Assistant Professor in 1987, where he continues to serve today as a Professor of Pharmaceutics. Dr. Hochhaus' research is interested in evaluating inhalation drugs through *in vitro* and pharmacokinetic/dynamic approaches.

He collaborates with regulatory authorities to improve methodology for drug approval of generic inhalation drugs. Dr. Hochhaus is a Fellow of AAPS and the American College of Clinical Pharmacology (ACCP). In 1998, he was recipient of the young investigator award of the German Airway and Lung Research Society and received ACCP's Tanabe Young Investigator Award. He was awarded the University of Florida Foundation Research Professorship in 2006 and 2015. He has published more than 220 research papers.



**Almut Winterstein, Ph.D.**, received her pharmacy degree from Friedrich Wilhelm University in Bonn, Germany and her PhD in Pharmacoepidemiology from the Charité Humboldt University in Berlin, Germany. She holds the position of Professor and Chair in the Department of Pharmaceutical Outcomes and Policy at the College of Pharmacy and is the Director of the Center for Drug Evaluation and Safety, both at the University of Florida (UF). She also has an affiliate appointment in the

Department of Epidemiology at UF. Her research interest has centered on the post-marketing evaluation of drugs in pediatrics and perinatal care, infectious disease and psychiatry and the evaluation and improvement of quality surrounding medication use using real-world data. In 2017, she was named the Dr. Robert and Barbara Crisafi Chair for Medication Safety in recognition of her research on drug safety and medication use. As internationally recognized expert in drug safety, she has chaired the Food and Drug Administration's Drug Safety and Risk Management Advisory Committee from 2012-2018 and was inducted as fellow of the International Society of Pharmacoepidemiology in 2013.



**Patrick Antonelli, M.D.,** is a professor of Otolaryngology, Neuroscience, and Speech, Language, and Hearing Sciences at the University of Florida. He completed undergraduate, medical school, graduate school, and otolaryngology residency training at the University of Minnesota. After fellowship training in neurotology and skull base surgery at the Michigan Ear Institute, he joined the University of Florida. He has served as Chair of Otolaryngology since 2004 and has previously served as assistant dean for clinical informatics and Shands HealthCare Chief Medical Information Officer. Dr.

Antonelli is a fellow of the American Academy of Otolaryngology-Head and Neck Surgery, the American College of Surgeons, the Triological Society, the American Neurotology Society, and the American Otological Society. Dr. Antonelli has given over 200 invited scientific presentations. He has authored over 200 scientific publications and book chapters. Dr. Antonelli maintains a busy neurologic practice and an active research program that is focused on otologic implant infections, prevention of iatrogenic hearing loss, ototoxicity, and medication errors. Dr. Antonelli has been recognized with numerous awards for teaching, research, and clinical service.




**Ina Richling, Pharm.D.** Licensed pharmacist with Doctor of Pharmacy degree and 15 years of experience providing pharmacy services in retail and hospital settings. Head of a retail pharmacy in Iserlohn, Germany. Beginning in September 2019 clinical pharmacist in a hospital (Katholische Kliniken im Märkischen Kreis, Iserlohn, Germany). She studied pharmacy from 1995 to 2000 at the Rheinische-Friedrich-Wilhelms-University, Bonn, Academic Degree: MSPhand received my Doctor of Pharmacy degree from the University of Florida College of Pharmacy in 2010 Lecturer for various pharmacy chambers in the area of continuing education and for the medication review project (Apo-AMTS) from the

Westfälische Wilhelms-University of Münster, Germany. Lecturer of the medication review project (Apo-AMTS) from the Westfälische Wilhelms-University of Münster, Germany. Member of the project leader team, lecturer and tutor of a medication review project (“ATHINA - drug therapy safety in pharmacies”) since 2013 Member of the Commission Drug Therapy Management (AMTM) and Drug Therapy Safety (AMTS) of the German Society of Internal Medicine (DGIM), individual member of the Pharmaceutical Care Network Europe associate member of the German Society for Clinical Pharmacy freelance writer for the German Pharmacist Journal Deutsche Apotheker Zeitung Publisher of the book „Medikationsanalyse Grundlagen und Fallbeispiele“ (MTM) Co-Author of the book Rose/Friedland “Angewandte Pharmakotherapie”



**Joshua Brown, Pharm.D., Ph.D.**, joined the Department of Pharmaceutical Outcomes and Policy as an assistant professor in 2016. He has experience in clinical pharmacy, health economics and outcomes research, and pharmacoepidemiology across academic, pharmaceutical industry, and managed care settings. His past and ongoing clinical interests have been in the cardiovascular and hematology/oncology therapeutic areas including comparative effectiveness and safety research with a focus on anticoagulation and quality of care in thrombotic conditions such as atrial fibrillation, venous thromboembolism, and cancer. His current research program and collaborations focus on research methods for pharmacoepidemiologic and pharmacoeconomic generic and biosimilar evaluations and real-world evaluations of drug-drug interactions. His academic work has been funded by the NIH, FDA, Bill & Melinda Gates Foundation, and the PhRMA Foundation in addition to contracts with pharmaceutical industry. Josh has published over 60 research articles and holds several editorial positions with specialty journals in pharmacy and cardiovascular diseases. Dr. Brown was awarded as the Academy of Managed Care Pharmacy Foundation's "New Practitioner" for his early career contributions and as a National Academy of Medicine Emerging Leader in 2019.



**Thomas Munyer, M.S.**, Clinical Associate Professor, retired 2015 from University of Florida, College of Pharmacy. Editor-in-Chief, PharmacotherapyFirst, An Electronic Learning Resource, American Pharmacist Association (APhA), PharmacyLibrary. Graduated University of Florida 1972, 1974, 1976. Faculty member for 35+ years. Developed the first Case-Based Didactic course for the College of Pharmacy, 1980-1991. Developed the first case-based Pharmacotherapy Course for the College, 1992-1997. Expanded and Coordinated three (3) of the six (6) Pharmacotherapy course sequences, 1997-2015. Developed and Coordinated the three (3) Pharmacotherapy sequence courses across four separate campuses for ~300 students, 2003-2015. Developed an Electronic Pharmacotherapy Learning resource covering over 130 Disease States distributed and available to over half of the 140+ Colleges of Pharmacy across the United States and foreign countries. 2015-present.



**Robert Bell, Ph.D.**, is President / Owner of Drug and Biotechnology Development LLC, a consultancy for biological, drug and device development. Dr. Bell received his B.S. in Chemistry, M.S. in Food Science and Human Nutrition and Ph.D. in Pharmaceutics from the University of Florida. His employment history includes Carter-Wallace, Inc., AL Pharma, UDL Laboratories, Inc., Somerset Pharmaceuticals, Inc. and Barr Laboratories, Inc. Dr. Bell is an Adjunct Professor of Pharmaceutics, and recipient of the Distinguished Alumnus Award from the UFCOP and former Affiliate Faculty at the

COPVCU. Dr. Bell has published and presented extensively, and has been issued ten patents with several patents pending. Research interests include drug, biologic, vaccine and device development, women's health, oncology, opioid overdose and addiction therapies, quality and green eco-friendly initiatives. Dr. Bell is a Member of the Council of Experts, General Chapters-Biological Analysis, the Joint Standards Subcommittee, and Chair of the Cell Banking Expert Panel for United States Pharmacopeia, an Editorial Advisory Board Member for several journals, and Co-Editor of the book *Poorly Soluble Drugs: Dissolution and Drug Release*. Dr. Bell participated as a member of AAPS, ASCO, AUA, ACS, ACCP, the Visiting Scientist Program and serves on several corporate boards.



## Organizers

**Prof. Hartmut Derendorf**  
**Prof. Almut Winterstein**  
**Prof. Stephan Schmidt**  
University of Florida

**Dr. Matthias Füth**  
Global Gator Club e.V.

*The generous support of*

University of Florida, College of Pharmacy

Bayer

Boehringer Ingelheim

Drug & Biotechnology Development

Merck KGaA

PKPDyne, Inc.

Roche

Sanofi

*is gratefully acknowledged.*



Global Gator Club e.V.

Please send your updated contact information to  
LaZendra Danforth  
[lbdanforth@cop.ufl.edu](mailto:lbdanforth@cop.ufl.edu)